GENE ONLINE|News &
Opinion
Blog

2021-07-10| Asia-Pacific

Sparx Therapeutics to Build a Massive Manufacturing Plant in China for Multi-Specific Antibody Production

by Tyler Chen
Share To

Founded just around 3 years ago, a small Chicago biotech is prepared to build a huge production center in the Yangzhou Economic Zone, China, to increase manufacturing capacity for its antibody-drug pipelines.

On July 8th, Sparx Therapeutics announced the plan to establish a 1.2 million-square-foot plant in China and is estimated to begin operating at the end of 2022.

 

Increasing Capacity for Commercial Production

The new plant in China will include a 400,000-square-foot cGMP cleanroom and a total bioreactor capacity of 80,000-liters in separate cleanroom suites. The goal is to produce five commercial products simultaneously and fulfill the needs of chemistry, manufacturing, and controls (CMC) for over 12 programs in clinical trials.

“The planned facilities, with a total bioreactor capacity of 80,000-liters, will provide sufficient quantities of drug substances and drug products to support preclinical and clinical development and ultimately commercial launch”, said Dr. Gui-Dong Zhu, CEO of Sparx.

 

Targeting Solid Tumors with Multi-Specific Antibody

Sparx develops multi-specific antibody and antibody-drug conjugate (ADC) discovery platforms to target solid tumors such as gastric and colon cancer. 

Currently, the firm has three first-in-class candidates in the preclinical stage and three candidates ready for an investigational new drug (IND) application. Its R&D power has also attracted Eli Lilly’s distinguished research fellow, Dr. Victor Wroblewski, to join as the senior VP and the head of biology.

Aside from the expected plant in Yangzhou Economic Zone, Sparx has in-house facilities in Chicago and China to manufacture clinical and commercial drug substances but feels the need to expand as they couldn’t meet the development needs for antibody production, especially commercial use.

Related Article: Gilead’s Yescarta Becomes First CAR-T Therapy to Score Regulatory Approval in China

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
GeneOnline’s Weekly News Highlights: Nov 13-Nov 17
2023-11-20
Pioneering Partnership: Africa CDC and China CDC Elevate Public Health Initiatives
2023-11-20
Biotheus Collaborates with BioNTech for Global Development of Cancer Therapy
2023-11-08
LATEST
BIODND – An AI-Powered Database That Breaks New Ground in Life Science Business Development
2023-11-29
GeneOnline’s Weekly News Highlights: Nov 20-Nov 24
2023-11-27
SK Bioscience and Hilleman Laboratories Join Forces for Ebola Vaccine Development
2023-11-23
BeiGene to Expand Oncology Pipeline Through ENSEM Therapeutics Partnership
2023-11-23
Advancing the Frontiers of Cell and Gene Therapy – An Interview with Dr. Shin Kawamata
2023-11-21
Astellas and Pfizer’s Drug Receives FDA Approval as Treatment for High-Risk Prostate Cancer Recurrence
2023-11-21
GeneOnline’s Weekly News Highlights: Nov 13-Nov 17
2023-11-20
EVENT
2023-11-30
2023 Healthcare+ EXPO・Taiwan
Taipei , Taiwan
Scroll to Top